<SEC-DOCUMENT>0001140361-24-017141.txt : 20240402
<SEC-HEADER>0001140361-24-017141.hdr.sgml : 20240402
<ACCEPTANCE-DATETIME>20240402071035
ACCESSION NUMBER:		0001140361-24-017141
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240402
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240402
DATE AS OF CHANGE:		20240402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40782
		FILM NUMBER:		24812201

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20025692_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:roiv="http://roivant.com/20240402" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_d723cebd2fc543188871c1f3753ce51e" contextRef="c20240402to20240402" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_779593046f8f456ea1008eba928538e6" contextRef="c20240402to20240402">0001635088</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="roiv-20240402.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240402to20240402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-02</xbrli:startDate><xbrli:endDate>2024-04-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
  <div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, DC 20549</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_3518fcbc007144b582ed34fdc2500781" contextRef="c20240402to20240402">8-K</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Securities Exchange Act of 1934</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_c79f5a6926824d4eb1811ac4419bd40c" contextRef="c20240402to20240402" format="ixt:date-monthname-day-year-en">April 2, 2024</ix:nonNumeric></div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-size: 24pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_ba4f731eefdb4672854dab27f2994e19" contextRef="c20240402to20240402">Roivant Sciences Ltd.</ix:nonNumeric></div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact Name of Registrant as Specified in Charter)</div>

      <div>
        <div style="text-align: center;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_0e1c454b261f43a4b456b27bafe0d60f" contextRef="c20240402to20240402" format="ixt-sec:edgarprovcountryen">Bermuda</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 34%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_5acfeea8e0474a059dabaddb683c2c98" contextRef="c20240402to20240402">001-40782</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_49c55ff55bd84c3a87fac92e60ebb5e5" contextRef="c20240402to20240402">98-1173944</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(I.R.S. Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_db920de0c6f54c5dbb4818486f404f4a" contextRef="c20240402to20240402">7th Floor</ix:nonNumeric><br/>
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_1b33b5ec366441b7be1e125a5694b881" contextRef="c20240402to20240402">50 Broadway</ix:nonNumeric><br/>
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_940480e8a5ae4061960547ac0827ccb3" contextRef="c20240402to20240402">London</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_ab6ffae1f0384fac8551d31ce7e18a8d" contextRef="c20240402to20240402">SW1H 0DB</ix:nonNumeric></div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_93257f5c88e847fda44225a71cc972a4" contextRef="c20240402to20240402" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric><br/>
        </div>

      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Address of Principal Executive Offices, and Zip Code)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">+44 <ix:nonNumeric name="dei:CityAreaCode" id="Fact_04fd9c5890044858b9f689edeab8f472" contextRef="c20240402to20240402">207</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_bdaa701cdbc844569779ec1599cb0255" contextRef="c20240402to20240402">400-3347</ix:nonNumeric></div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Registrant&#8217;s Telephone Number, Including Area Code</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not Applicable</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former Name or Former Address, if Changed Since Last Report)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
        registrant under any of the following provisions (<span style="font-style: italic;">see</span> General Instruction A.2. below):</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </span></div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 22.5pt;">
                <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_59999e08c6264086894ade88028b7cf8" contextRef="c20240402to20240402" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
                  </span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><span style="color: rgb(0, 0, 0);">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></span></div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </span></div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 22.5pt;">
                <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_0d7f63f9c88d4b5aaf80ea8a5820bcad" contextRef="c20240402to20240402" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
                  </span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><span style="color: rgb(0, 0, 0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></span></div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </span></div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 22.5pt;">
                <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_3912ea0b6a4e49b494c3ea4c0b375841" contextRef="c20240402to20240402" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
                  </span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><span style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
                      240.14d-2(b))</span></span></div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 22.5pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_a36226a17de64c4289e1f0f4a03f96dd" contextRef="c20240402to20240402" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">
              <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Title of each class</div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; padding-bottom: 2px;">&#160;</td>

    <td style="width: 28%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Trading Symbol(s)</div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; padding-bottom: 2px;">&#160;</td>

    <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which registered</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_bf1fa18931494d73a4be2e0f4b414dc7" contextRef="c20240402to20240402">Common Shares, $0.0000000341740141 per share</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#160;</td>

    <td style="width: 28%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_8202e2bab94b47ac852e09ab0f879fd4" contextRef="c20240402to20240402">ROIV</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#160;</td>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_c4a0f630e4ec46b3a7fabc05e5879f1d" contextRef="c20240402to20240402" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
      </div>

      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
          1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</div>

      </div>

      <div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_545c6018c4244a35893e5f8688169ba2" contextRef="c20240402to20240402" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;">If an emerging growth company, indicate by check mark if the
            registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="font-weight: normal;"> </span><br/>
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 72pt;">
                <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Item 8.01.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <div style="text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; color: rgb(0, 0, 0);">Other Events.</span></span></div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: normal;">Data Release</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;">On April 2, 2024, Roivant Sciences Ltd. (&#8220;Roivant&#8221;) </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">issued a press release announcing positive NEPTUNE study results for brepocitinib in non-anterior non-infectious uveitis, as well as authorization by Roivant&#8217;s board
            of directors for an up to $1.5 billion common share repurchase program, including the repurchase of all common shares held by Sumitomo Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) for <span style="color: rgb(0, 0, 0);">approximately $648.4 million</span>.<span style="color: rgb(0, 0, 0);"> A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item 8.01.</span></span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">As described in the press release, Roivant will host a conference call and webcast to discuss the NEPTUNE results and its share repurchase program
          at 8:00 a.m. EDT on <span style="color: rgb(0, 0, 0);">April 2</span>, 2024.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </div>

        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: normal;">Share Repurchase</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Roivant&#8217;s board of directors has authorized a common share repurchase program, allowing for repurchases of Roivant common shares in an aggregate
          amount of up to $1.5 billion (excluding fees and expenses). The repurchase program will be funded with available cash and cash equivalents on hand and does not have an expiration date. The timing and total amount of common shares to be
          repurchased will depend on several factors, including the market price of the company&#8217;s common shares, general business, macroeconomic and market conditions and other investment opportunities. Under the repurchase program, purchases may be
          conducted through open market transactions, tender offers or privately negotiated transactions, including the use of trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;">Pursuant to the share repurchase program, on </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">April 2<span style="color: rgb(0, 0, 0);">, 2024 Roivant entered into a share repurchase agreement with </span>Sumitomo <span style="color: rgb(0, 0, 0);">to
              repurchase all 71,251,083 common shares held by Sumitomo at a purchase price per share of $9.10, for an aggregate purchase price of approximately $648.4 million. The repurchase transaction with Sumitomo is expected to close on or about April
              4, 2024.</span></span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">The share repurchase program may be suspended or discontinued at any time. There can be no assurances as to how many additional common shares the
          company will repurchase under the program, if any, or at what prices any purchases will be made.</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">(d) Exhibits.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Exhibit No.</div>
            </td>

    <td style="width: 1.43%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 87%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Description of Exhibit</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: normal;"><a href="ef20025692_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 1.43%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

    <td style="width: 87%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: normal;">Press Release dated April 2, 2024</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: normal;">104</div>
            </td>

    <td style="width: 1.43%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

    <td style="width: 87%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: normal;">Cover Page Interactive Data File (embedded with Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SIGNATURES</div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
          on its behalf by the undersigned hereunto duly authorized.</div>

      </div>

      <div>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span></div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; font-weight: bold;">ROIVANT SCIENCES LTD.</div>
            </td>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 47%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; font-weight: normal;">By:</div>
            </td>

    <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-weight: normal;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Matt Maisak</div>
              </div>
            </td>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; font-weight: normal;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

    <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; font-weight: normal;">Name: Matt Maisak</div>
            </td>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

    <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; font-weight: normal;">Title: Authorized Signatory</div>
            </td>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

    <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; white-space: nowrap;">&#160;</td>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top;">
              <div style="font-weight: normal;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Dated: April 2, 2024</div>
              </div>
            </td>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

    </div>

    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/> </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20025692_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold; font-size: 10pt;">Exhibit 99.1</font><font style="font-size: 10pt;"><br>
      </font></div>
    <div style="text-align: right;"><font style="font-weight: bold;"> </font><font style="font-size: 10pt;"><br>
      </font>
      <div style="text-align: left; color: rgb(63, 63, 63); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion
        Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million</div>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbad08fb06ece4b6ca2303377493a51fd">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Roivant&#8217;s board of directors has approved a share repurchase program for up to $1.5 billion of the company&#8217;s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for
                $648 million</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z53c95f2f5e6d4879bceb51862de5ecbc">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Sumitomo Pharma repurchase reduces shares outstanding by 9%</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z21fe7ac5bb87463a89fd01b54fa59e35">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies
                measuring this registrational endpoint</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdacc0ea2f09543489182446190324917">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">29% of subjects receiving brepocitinib 45 mg and 44% of subjects receiving brepocitinib 15 mg met the pre-specified primary efficacy endpoint of Treatment Failure at week 24 (lower failure rates
                reflect greater treatment benefit).&#160; The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32b0479382da4663a1a0924663950a07">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">All secondary efficacy endpoints were also positive and dose responsive, including measurements of potential benefit on prevention and treatment of uveitic macular edema</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z64dcc229221d49ca9605b5a99c91203c">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">NEPTUNE represents the seventh positive Phase 2 study for brepocitinib with over 1,400 subjects and patients treated with brepocitinib in clinical trials. Brepocitinib was generally safe and
                well-tolerated in the study; no new safety and tolerability signals were identified</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zecd057090c514239895eb76a3eaa1f43">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Brepocitinib is well positioned to support a potential multi-blockbuster franchise in specialty autoimmunity with an ongoing pivotal study in dermatomyositis on track to read out in calendar year
                2025 and expected initiation of a pivotal program in NIU in the second half of calendar year 2024</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za295602afa94421c8873c1abcd2ecdfe">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Roivant will host an investor call to discuss the updates at 8 a.m. EDT on Tuesday, April 2, 2024</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">BASEL, Switzerland and LONDON and NEW YORK, April 2, 2024 (GLOBE NEWSWIRE) &#8211; Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the
        Phase 2 study (NEPTUNE) <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the </font>strongest efficacy data in NIU observed to date<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">. Roivant also announced </font>that its board of directors has authorized a share repurchase program for up to $1.5 billion of the company&#8217;s common shares, including the repurchase of
        all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share. The aggregate purchase price for the Sumitomo Pharma transaction is approximately $648.4 million and will reduce Roivant&#8217;s shares outstanding as of February 9,
        2024 by approximately 9%.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The striking NIU data underscore Roivant&#8217;s continued commitment to developing effective medicines in underserved indications with high unmet need, such as for these
          patients who are at risk of blindness. We are extremely pleased to share these positive data. We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma. This
          transaction along with further potential buybacks reduces shareholder concentration and efficiently retires shares, increasing our continuing shareholders&#8217; exposure to developments in NIU and to the rest of our upcoming clinical data and company
          progress,&#8221; said Matt Gline, CEO of Roivant.</div>
        <div style="font-size: 10pt; text-align: left;">&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily. Patients, physicians,
          and the study team were blinded to dose. All subjects received a 60 mg/day prednisone burst at study entry for two weeks and were tapered off prednisone per protocol by week 8 (six-week steroid taper). Subjects were evaluated for Treatment
          Failure, a registrational composite endpoint comprising multiple measures of ocular inflammation and visual acuity, as well as discontinuation due to intercurrent events or initiation of rescue therapy. The study&#8217;s primary efficacy endpoint was
          the Treatment Failure rate at week 24.</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter"></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">At week 24, 29% (5/17) of subjects in the brepocitinib 45 mg arm and 44% (4/9) of subjects in the brepocitinib 15 mg arm met Treatment Failure criteria, with lower
        failure rates reflecting greater treatment benefit.&#160; The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm.&#160; These observed results represent approximately twice the observed benefit as
        seen in the corresponding registrational study for the only approved non-steroidal therapy in NIU.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive. Of patients in the
        brepocitinib 45 mg arm who met the threshold for uveitic macular edema at baseline, 43% achieved resolution of macular edema by week 24. No patients in the brepocitinib 45 mg arm who entered the study without macular edema developed macular edema
        by week 24.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Safety and tolerability were consistent with prior clinical studies of brepocitinib, with no new safety or tolerability signals identified. Brepocitinib has been dosed in
        over 1,400 subjects and patients with a safety profile that appears consistent with approved and widely prescribed JAK inhibitors. Additional safety and efficacy data will be presented at a future medical conference.&#160; </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Non-infectious uveitis is a devastating disease that can lead to severe visual impairment and contribute to tens of thousands of cases of legal blindness in the United
        States each year, including many instances of irreversible blindness,&#8221; said Quan Dong Nguyen, MD, MSc, FARVO, FASRS, NEPTUNE investigator and Professor of Ophthalmology at the Byers Eye Institute, and Professor of Medicine and Pediatrics at
        Stanford University School of Medicine. &#8220;Current treatment options provide inadequate benefits to many patients; thus, novel pharmacotherapeutic agents with better efficacy and more convenient methods of administration are urgently needed.
        Brepocitinib&#8217;s striking results on multiple endpoints of clinical significance position the drug to become a potentially transformative once-daily oral therapy for this debilitating disease and reinforce the distinctive mechanistic benefits of dual
        TYK2/JAK1 inhibition for highly inflammatory autoimmune diseases with multiple pathogenic cytokines, such as non-infectious uveitis.&#8221;</div>
      <div style="font-size: 10pt; text-align: left;">&#160; <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The NEPTUNE study was designed to minimize likelihood of false signals of benefit, by tapering patients with active disease from 60 mg/day of prednisone to 0 mg/day in
        just six weeks, more than twice as fast as steroid tapers in precedent studies,&#8221; said Ben Zimmer, CEO of Priovant. &#8220;Against that backdrop, we are thrilled to see a failure rate of only 29% in the brepocitinib 45 mg arm, better than any precedent
        study was able to achieve even with more lenient tapers. The magnitude and consistency of dose-dependent benefit across multiple independent measurements of inflammation, visual acuity, and macular edema give us high confidence heading into Phase
        3. The results further point to a potentially highly differentiated product profile for brepocitinib in NIU&#8212;an orphan indication with high prevalence, severe morbidity, and few other therapies approved or in development.&#8221;</div>
      <div style="font-size: 10pt; text-align: left;">&#160; <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Priovant intends to initiate a Phase 3 program in NIU in the second half of calendar year 2024. The company would like to thank all of the investigators and patients who
        participated in the NEPTUNE study.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter"></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The ongoing Phase 3 study evaluating brepocitinib in dermatomyositis is expected to be fully enrolled in the third calendar quarter of 2024, with data expected in
        calendar year 2025.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Share Repurchase Program &amp; Sumitomo Pharma Repurchase</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Roivant&#8217;s board of directors has authorized a common share repurchase program, allowing for repurchases of Roivant common shares in an aggregate amount of up to $1.5
        billion. The repurchase program will be funded with available cash and cash equivalents on hand and does not have an expiration date. The timing and total amount of common shares to be repurchased will depend on several factors, including the
        market price of the company&#8217;s common shares, general business, macroeconomic and market conditions, and other investment opportunities. Under the repurchase program, purchases may be conducted through open market transactions, tender offers or
        privately negotiated transactions, including the use of trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.</div>
      <div style="text-align: left; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the share repurchase program, on April 2, 2024<font style="font-family: 'Times New Roman';">,</font> Roivant entered into a share repurchase agreement with
        Sumitomo Pharma to repurchase all 71,251,083 common shares held by Sumitomo Pharma at a purchase price per share of $9.10, for an aggregate purchase price of approximately $648.4 million. The repurchase transaction with Sumitomo Pharma is expected
        to close on or about April 4, 2024.</div>
      <div style="text-align: left; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The repurchase program may be suspended or discontinued at any time. There can be no assurances as to how many additional common shares the company will repurchase under
        the program, if any, or at what prices any purchases will be made.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investor Call</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">An investor call and webcast will be held at 8 a.m. EDT on April 2, 2024, to discuss the Phase 2 NEPTUNE study results for brepocitinib in NIU and Roivant&#8217;s share
        repurchase program. To access the conference call by phone, please register online using this <u>registration link</u>. The presentation and webcast details are also available under &#8220;Events &amp; Presentations&#8221; in the Investors
        section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant&#8217;s website after the conference call.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Priovant </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment
          options. The company&#8217;s lead asset is brepocitinib, a dual selective inhibitor of TYK2 and JAK1.&#160; Through dual TYK2/JAK1 inhibition, brepocitinib is able to distinctively suppress key cytokines linked to autoimmunity&#8212;including type I IFN, type II
          IFN, IL6, IL12, and IL23&#8212;with a single, targeted therapy. Brepocitinib has generated positive data in seven Phase 2 studies with oral once-daily administration. Brepocitinib is currently being evaluated in a Phase 3 program for dermatomyositis
          and is entering a Phase 3 program for non-infectious uveitis.</div>
        <div style="font-size: 10pt; text-align: left;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter"></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          <div class="BRPFPageHeader"></div>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Roivant</div>
        <div style="font-size: 10pt; text-align: left;">&#160;</div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines
          that matter. Today, Roivant&#8217;s pipeline includes VTAMA&#174;, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the
          neonatal Fc receptor (&#8220;FcRn&#8221;) in development across several IgG-mediated autoimmune indications; brepocitinib, a novel TYK2/JAK1 inhibitor in late stage development for dermatomyositis, non-infectious uveitis, and other autoimmune conditions, in
          addition to other clinical stage molecules. We advance our pipeline by creating nimble subsidiaries or &#8220;Vants&#8221; to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and
          health technology startups complementary to its biopharmaceutical business. For more information, <u>www.roivant.com<font style="font-family: 'Times New Roman';">.</font></u></div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Roivant Forward-Looking Statements</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered
          forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which are usually identified by the use
          of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and variations of such words or similar expressions. The
          words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking
          statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies
          regarding the future, and statements that are not historical facts, including statements about potential share repurchases, the clinical and therapeutic potential of our products and product candidates, the availability and success of topline
          results from our ongoing clinical trials and any commercial potential of our products and product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including
          any underlying assumptions, are forward-looking statements.</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give
          no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks,
          uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing
          environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release and are subject to certain risks and
          uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as
          a result of new information, future events or otherwise.</div>
        <div style="font-size: 10pt; text-align: left;">&#160;</div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter"></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader"></div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contacts:</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>Investors</u></div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Roivant Investor Relations</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>ir@roivant.com</u></div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>Media</u></div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Stephanie Lee</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Roivant Sciences</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>stephanie.lee@roivant.com</u></font><font style="font-size: 10pt;">&#8239;</font></div>
      </div>
      <div style="text-align: left; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>Research</u></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Daniel Herz-Roiphe</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Priovant Therapeutics</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>daniel.herz-roiphe@priovanttx.com</u></div>
      <div style="text-align: left; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>roiv-20240402.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<xs:schema targetNamespace="http://roivant.com/20240402" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:roiv="http://roivant.com/20240402" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="roiv-20240402_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="roiv-20240402_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://roivant.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>roiv-20240402_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>roiv-20240402_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://roivant.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="roiv-20240402.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139663486954848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  02,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Roivant Sciences Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001635088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1173944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">50 Broadway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SW1H 0DB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-3347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, $0.0000000341740141 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ROIV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;OX>:*J,!4_Y1V9'7]0&Q=DS^T3H+8I7=0:&VWH^<R-8U!ZGP05\VL5 JI;
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !0.8)8'#AEZC\!   \ @  #P
M 'AL+W=O<FMB;V]K+GAM;(U1RV["0 S\E=5^0!-0BU1$N)0^D*H6E8K[DG6(
MQ3XBKP,M7U\G452D7GKR>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@
MR*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_<Z[
M5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3 QFU+BLX5>C(,=D",Y1]X
MVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AH
MQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL
M(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W
M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ 4#F"6"0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( % Y@EAED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !0.8)8A=[+K^X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !0.8)8
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( % Y@ECM]CY#800  "P1   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !0.8)8
MGZ ;\+$"  #B#   #0              @ &D#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( % Y@EB7BKL<P    !,"   +              "  8 /  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( % Y@E@<.&7J/P$  #P"   /
M      "  6D0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !0.8)8)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !0.8)899!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20025692_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20025692_8k.htm">ef20025692_8k.htm</File>
    <File>roiv-20240402.xsd</File>
    <File>roiv-20240402_lab.xml</File>
    <File>roiv-20240402_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20025692_8k.htm": {
   "nsprefix": "roiv",
   "nsuri": "http://roivant.com/20240402",
   "dts": {
    "inline": {
     "local": [
      "ef20025692_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "roiv-20240402.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "roiv-20240402_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "roiv-20240402_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://roivant.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240402to20240402",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20025692_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240402to20240402",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20025692_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://roivant.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-24-017141-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-017141-xbrl.zip
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ML!/QX@JL<IQ^ !$^1*!:&OPSBN<6;7,P^9JN14MQ7;RD4\%#@;0YECHECN^
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M[7L1CZ><K6BO)7DIL5_U5LJ;$8Y^]X3[* ,!;:Z(2U2RF.<+P6RAT1YEFN6
M+0'A<[NVZ1F>8S=*^>HM"L&E\>@T^/Z%YXK=GN8)84\)T I!J.-9EN];ELMM
MZIG,[OG,<PS1U83K6L)J0!#';NEZSW3HJO?Y,(K\HF[%R[=^()VWJQ09!HCG
M$!C&Y'\A($NXS")'<#TJ2N_MCZY(=H^C\5@F6/U 4&N0C$N_;=[? Q><MB_;
M@S8Y&4^": 9L4)55<A:UF^!@15SR+[_ 771YZI8!MIT-:NSV/F*,>8<N/.(\
M%DF2?WR6H=#+JZ:N8VA<:%[7MZAG<=>EMFY3N^N#EO,I:Z '>^F(? RB*-ZL
M!I=]Z.\(848)8;IKFF @/+/;I51W>Z[0A6Y8S.HZU+4;I7XM+5OSOV&S'PME
MQ_#U/+Z*;L(2PAR8M:T)FUE,4*VK.UW-HCWF:;;1\SS7;("PSU'(HW 95^NS
M5!6@+J(D9<'_R\F2X\S<KN\SH?N::5,P_K9EZ=S4/=$3NLULW@"NP5_Z[T3[
M\'YS3/\=T"WS\\M$,PVKYUN>;0N;]GS.*#6 R7NZYSD]@]$'1!5Y,($@8$#Q
M9RBQ@.8/B#]Y-+Z/'+R4W-YNCCUT7"YB&7IRP@)R<BN\:2JO!3GWP:*)9(^P
MD!/@/X(,6),Z^;%6*OZ'TO6"B0KB*!9L.8:E/@=_W'8TC5+;LEW'[]J.X(*Y
MMD][1@-1-+1><_WP.0+GZ&(4A:N!FLL9ZVFZQUW/IA!*.[V>(SS=<AS/U0RK
M25Q -:UEFG0%GI="H45^[V^_VH;>VT_(E0C$!/&1NZ![Z(D'4TP.$:278MT?
MG7//HI0<328!N*'@/;X4J'8_@AX%'SG+SL8DO\QUSQZ1/F9EPR'HT@'H($$^
MLR0EEVHM9ZO*YC[I^$I6;YM("=&H!+@@.A+>5UQ=)&PRB:-)+#&P=*-;XHH@
MND&T8"-BB]BM/X@O V1FF1")I9-<%7F21(ZG0<I"$4V38$82B#\2?Z:>S!^(
M7)@1*^)3:)@;I7B1)I_">#&H^5G>!V .  A\'M-H$B.\A.S6I+SQ>Y](<%"D
M![-*A,@SSN23"$4,]N0TA)=,LPCYJ&VTL_F][=^#$#O;2;9O".SF9-E*&G[-
MV,L^04UF?BDD:Y;Y]@*6)%FYZF>@Z!4^M)TD^,Y2N%JY.$CG*PAU\?I*^+TF
MX%>5+0OI7$X3K#Y79@^UC+ F7Y"/;QAMJRX;\')X;JV9_RN6*<@Z9EFF89Y<
M2,I)60?^A&9[7:-+-1M<#LJXL&W-L-V>YS=(RJXXN6X4!2X#X4]!%2%5G!ZE
M^TWR@ZL\O=QV/])F*G@39;/%HRW0=0NB71ZSCO0[ASDQ@20E:I))J0+E<@K"
M3@TK5\>HATLE'UCIL:OWR/''2V*86ALZOIWC^SYHK\_2YE^64T^O2OI52;\J
MZ4U*>A"!ZP,B&@Z_@ <';EQ0#@QYS^^:ON/9-J>NQ9AO:X+9S+(-S?58@QS-
MJX9^,@V]H"09YZ1<U<\Z92W=**GH2BG>7$%3K9WU?-71KSKZ54<_LXZ^B 4Z
MT5C$IHKA,7Z.SWV_DCDS'=T03'.[C KJN-2AGBD8]337[%DV;; P\JJKGTQ7
M T5;7HFD5;<ZJ=/;O&7LNF_OT-PU9,"_3)]G([QJ].?1Z,UT^%9J_^XN\*NW
M%=]:]G>'"E_S5*Z8ZZ7[,7.83?7M:9),15RO=9G9-8PNTWM<=*E'#=O!%4V?
M,@W<YBY_2@^Y,<*S2M9:=*]RSI9PO:&695L:TA0MNNO=I2$S79CW_5[*7)XG
MQU_*WF3)=A$+7D'\?-.1,DUY\AV0O2$[OB78:E=#?L9*:VM=O=G2MG5COC-]
M2= V2&;=>EAC!VNK2W,[AU=X5DBV:\H;9>9KC>OR\.(]?5NU>S4KB21GP3)!
M'F K[9^%W#%3J]^#V1@@V4WJ-/6/3NR?1K:+G4]*M$5AM,&NW(PDW%D8GX<R
M07WT\NTZ]O&=H_M8_*:U9[E=G^F&J[1JN?S&UWVFVXZI4X?R'NYG$88 ?]:E
M$#]ZO0;E-^@Y ^D&(Q9C\=5O6CNS=9I)]1[5=*J3"1XQ@^V/O97B,65\B[K[
M:=EH>YL]<B6=Z>@2%]G #<)PF>L W_2PM!-XR&&NYML]Q^<-JA</+\]/_^^G
MXHZ7HF2VQQV%FBFBL*4-OA[$R'[7U 05'NVZ)NOYS/4T2UC()/I#(F<T'45]
MZQ5$(F<LX>Q?Y%,003P-P4H X0KYPN*O(GVL+4./$!PVR#D]9&/$X\>/IR''
M<%T0=T8\52\V!MR#41=J\Q'&BJ4B+ID0%A*(]7&#[9 ,X^@F'6'4/\'"+I80
M+GP99ON@LU(#S2I"SJ4Z@\@OD4AW3',>_*-0]O95_4'Q-+P7^'."VZJQOB_+
M)1ANRZ@9O.[<BN6Q,;VP>+PT>ONN,NJ[:98O<SP@O?!46=:3-?2[HQ"^>.R3
M>NHX>ZA<*D0MKZOIMD<-2IEI@8<B+-_NVK;>=5S6H$+YH6FVVEQN0](]4G:Y
MV>:&AZ7OGI!53OT- K\'8EZK/62U"A3_2DID!'I"J7G0$V&D<E331"@Q!M3D
M=:=XSJW,RI?4,2K(&NJ]P0P!N9$ !O)L"/."EEA<2SR4%+0/"SU<56>>VDR!
MG?%X8<YBGF25IGQ=@LS<9?,$65F+M,F<\6I/.GA1U*U[?/TZ2Y.C'![[2):-
M)SFN'-98/LEQY9C'YSG)<3V"O$"P&+VP=#1_.(-<D3*_,S^U4N&H6/9Y?WGQ
M\8(-Q?M8L*^XP6"G7H%-H$_+Q4XMYJ>(2!;<L%FR9J2*DUFB0@9+AG"%O;K\
M:7Y/6V#ZO@=ZE#%RUZ$</U%]Q3WK)'K&,U1)U 46IZD8$[NMZ>VGJ21XXN*!
M3<HT2R+6+XQE._=/\,BPI/V,:_GWG^^Z'2S/$*M4-WZL<5 ^L)212W G6"(V
MV>57-V^3FW<>DLI1<7ND]EPNLHN[X0QM/V]55_K^V\<LVY"XL,\) ]\-]Y'&
M&:G!]PO!OGAJ^U"$GN*U(&<G%U=_GIT  %,^@Y[)-$@3Y3BZ>&Z?JKN4+L:F
MX&JT&%IY"8UX(4-?>8'3A$RO!73$+:D)N0'K@I]@Z4=1+/^=%=2#LUM"@-H<
MZ$;@7U8$&/Q(+F,8-(HS&  STPGZF[_I;8NX,@AP+"_+Q*I,*YXN.(W![X3Y
M@:<ZC-D87>QBDV$6B\][P L@,JH,D(!9#CC"-YB.)?@4$;F ^V/<F]C>JY*P
MZ#&G(<+8H"I*;26[E5B]&LS(;UUJMRD99[/)V:#=8!AR!)!/YIO!JL3%-$.:
M,H@H.,PH%H TAH']2+HR)8[3UM5^83D_"46H2<^/7,?]:U$6V-<8J#M]^.]0
M5ZP!X0@S,HD72S?+R:R@>B'H-T!",HJ2%$0-XO0"DQ[R&"+[1K@>[IH$Q'*9
M>%,8 T<K9*Z0-D47^%S'T"4982FQ^YI&6'O<)B<?KG QJ0'GY(HJIV.FK]HO
MG)Q/;175P@YN<,VQ_\+1LR40:I5R51&/2LI<694[]2\K=JGZ*LU0=% G&A2R
M4]7!(&? PVPXC,405%.9X\>8DL G:RS!KK@M-+TO1"9)XG:"/[:2O&V3JU$=
M?)G8NH+X4Y4WR?(BUTP&6;3$DI$:2'U1/Y/" G1*4=9&V(#_>02OPTS,B%T+
ME>^YG<CL?"F"I\MF+T_E&&'#!](HQ0S+?#;5^</$W/*L%U#S#%PN8%8<04C$
MM=K ZS-%GF5K-U;+ #!7Z8G"4N2YISF1*^_>(\-\2["+OSJC-G^/F1=' E1:
M-):> C\?%FYQF16JX=U(^>PRO!9)JHK9H@GN#Y^&*JW<)G_.2];JV&3!%V,V
MJ\X?WS-5V:YT!$'Q< 0CB[" 0F6ZF,I  ; J_17#7$'_)IC8@KE?9Z8V%,,H
ME<K659^IXFR:N09I7ILQ":!K7FZ7I<TUUVKI#?/FR@EB8Y63>^DZ]@6[U^4S
MP!'KZ[4-FL#'\Z4+TWFWD<W,ZES!J8R8<B'0%5N%GX&NRRI E0+*IS!W0AN\
M,(V60N+RZ* S>OJ>8>E[FFW>Y?$R]&!*F$7=,2]F0,;^#?Q'>&WND\_U]/(S
MZ%]O\'57-'))*#,LS"$"-Q05>:8"(N(%4:(J9Q  -YJF6>RU-'\Z]VQ^/K?U
M:H.,Y/J5)--DDJT5 !K1(XTPV:]"Q52M#("]RBQ7C'8PQ&="C".2:<Q41,N4
MJ1I%-S DKE[RS!JPY9BJNI11+)8I2U8";U'1O C=</%DMJ?H#)(Q8KDI2Q1\
M"XM1V/ QX^+.!<A'*5_^"?8]J)3ID^U?**='G2SZO*O&Y)%J_>]=UE\[D8_S
M=35U.NE8^9#H->5!>=+><B'&=A9K7TS4MJ+B\*<_EG'W!%-^+<;7C9H:KFP%
MKFG-[OUYX&8D4]%"' OD@9N8U2QE;*FDM$B3G45-9'(]GMJT[IC< E,/7UEH
M^'Z[]X/3Z8-*S$V*8[-RLCUZH70M_S^LAO%)L+7P2QG)?H93^(:F&5;7,?XI
M;AVGI;='Z7CG$-/"!QU6M\#V7$R_9B;;D(3'/:[ZWL2Y4$GE?!U.)8TX6?KQ
MH5>^KD>=KC5!SBO+;AOOQQ$ 2+ NAIQB>@-#]VM!U(*R.FE^5XQ=P>=9U5/U
M*^P$?ZR9\/PGOKZWO:FO]4C?6(^TC<JW;17U#TX_G1U=_7FY\NNYCU3Y^G*#
MJ>7\:HPK'7$>I3;-="^5NN-*$9\&,^*QJ?JY>UQ-SG\=4*UPD 1F)\J+_N#(
MX=*G*T8L\#$GJ?+QF!?*NJJU["FF4-7 BW6H+52=?Y<G=33\+;&?,6B%$1 3
M[W:,.?S/84_K] YN^SHZNR*#X].3L^.3 ?E\]>&;0DU+VYZW4.^H?)MK6>=?
MC27G@7B".)C6N5)/]O;OD30/<_KK=X,_7%CFFO+]K/\MPE%+_WOF0>X=T-3/
M9.F![2_(=I(.^<)2W/\G$_9UZ\<);(^;:]GE7K'32^'[K<1[&YGT.>+O^EGA
M[M;^'1SV',STRC<OFV_4"0Q]<K0H'!O ,RR-XMDK!_U('%0'TAJV>C9'ZE%I
MW3#L>'SGX5M_Q%OM#!&\?V<6^L5X%-]$UF?,*6YOW,KW%_7;X7/0#CINQ&>'
M\#E*Q\'A?P!02P,$%     @ 43F"6+\RI<^1&P  ]74  !4   !E9C(P,#(U
M-CDR7V5X.3DM,2YH=&WM76ESVTB2_;X1^Q]JU.,9.X*B>$JBY7:,W)9[M.UK
M)7=/S'XK $6B1KBF (AF__K-HPHH@)1L>7QUV(YVFP*!.O-X^3(+>A17:?+X
MO_]+B$>QDA%]@L^5KA+U^-$!_VLO_FE_7SS7H<I*%8DJ?RB>F%Q&1D<K)9[I
M3&:AEHFXS).ZTGE6#L1Y%O*C].=I'M:IRBH1&B4K:*(N=;;R&WE]\6JI$R4F
ML^%T.![.)Y.9]_Q/>;$Q>A578KQ8S,6^F(PF,__Q_7V>R(&=R:,@CS8B6(5Y
MDIL?]WY8TI\]45:;1/VXM\RS:G\I4YUL'HJ_OM&I*L5+M187>2JSOYX(^K[4
MOZN'8CPJJA-1J;?5ODST*GLH$K6$*]3R0_'#B/Z<[''_^&"G$Z^1O<<P/KS(
MMT;ZVJUN;$26E[&,X"G[84]0;S_NP9I7RC0CCQ4NPT,Q*]YNC4$$,KQ:F;S.
MHOW^5_X$N,D3D4JSTMD^SN>AD'65-Y<,=\+7@MQ$"MK*\DS9>?+PW9C\MNE)
MN&M[)=9VY$&>1-LKO/?X[&VL UV)Q6(XMNOTCN5\%)C'3DC<$P?>LOYG0VRW
MZ^[#:'Z\80@=$3*KX/[A="#X[P.[-G>1SEV#O\CUM81AGV89"$0(3;S.2UWI
M:R5>GKU^\^O+,W%9U: D%ZJLDZJ$1@QHE"KR$.[*="!T)EZ>_SH0LA1KE23X
M[Y-<FDB<UE6<&_V[1%VGY^H"C(+X,^BM>**3!"ZWRGL92Z.@EZ(V82Q+4'63
MKXQ,R48D=82&P/LV7XJSK-+PR&6=ZBI/<_$:6D@E#%=>*>KNSX>S8_&"._)W
MO+O@VSOUEQ_&AZ.3WA.5#,#NA###LI AC.;'O=$>_5S(*'(_?ZCA6.NHBO&'
MT;WWL2(B3&19_KCW]/+UL^>ZK-[@X/:$CG[<^SV0T>AX&8P.5:AFP6$H)]/1
M='IT-%M,Y7R\C/8>MXONV4Z8H7GL_XQ7(C<A-[[C1HYNE&TGX57TGLU=*U/I
M4"9NRE5>W%VX<=>.)Y/#D_?JF"W6SHZW%W^[JV[S.\3IYH$W&H?#'1^=E*"(
MJ"P@SQ%(<UCEIA0@X4(6A<FOP0=*49)JF%;X"U:-ODX%+.K85A6#K.9I(;--
MTQ'\G,*WU!JX7MVHE<R$7!D%?9F.@F$C:K>2E4[)^DLA6.O275IW@V3 !;-#
M)N$R2O4?4 /GTW Q7TZ6<W48S8Z/%D&H@OGX^' 2J;D*@_"[!GY9#>P+LR?U
M1D4U.D%6$I'7%4AZ1EH2;,3BWK<IT)/Q4AW)<!X$QT>SPZD\7BRCT3B8SY9R
MOE#3^7>!_K("?9Z1K7Y-(CQI@%M)P T,>0[ ;C^2\+S(#01@00^_ 63?U]D2
MO(_.ZU+4UPJ^*\5]P'4/!M3T;"[2%6@'8T!X'#YBH(;?!:JLQ!N,V"AV>P;]
MU.BO(((##0I*9:XI&A017!$2?!"XG) AYOFO-$JMRFU'DBI9U@95KXHU=KH"
ML32$)F$.*HN*7&?5MZF1D0S#D9*3Y6@QGTUGQXOQ\60V.QPO1M/);#$^^JZ1
M7U8C)XM[J'AE'?P+M J%-U3ZFMR(KWNL5N!@Q&SV7@^,Z8%4L>:!%NZ7A0KU
M4H.&%49#7+X1:KF$"8>;1D6PX6W]E!7$:^I*3&;B?I*OE1%+7W.W]=&H90)C
M$RLB9XRHFB8#E:FEKAX,.7(2;V!LNPV"6)H\!:1;*C159 5TM1'WX4H(:ZJS
MFO2[1/*AS,$;/Q!K ,/CXWMHI\C:[%@_DWZ;5F Z"4:SH\7T>!+)V2$XYK$<
M+2;X:3$?R=%W*_"%K<!IDHA2@6!'._42"1-4Q*3,1>%8%S0&44Y0M"Q $^":
M'ZNQ4U2H6"7J=9%7&**A4V<E!&>/=N$:K\)';*Y55'B G7LH4AG6B31"12J5
MWZ;Z',ZB,)Q,%I/).)HM0KDX',V#N5PLPL5X,II^C].^L/HX'-O S9(\0$G"
M';<JXW OXUTD13I.8JWAYARF(,:#V6C4^EC4C0+\#;=L4PYT=Q\@APE\@OG#
M7:!JY;#+@**'6H'V ;0&A%W*)6GQM@-%>G2_RA-EJ"?KT&C4)X#!10:3QZ?!
M(9+:TIV!3M!#EK#,T#-;#!VA=J/3_S855X71:'XT6HS"^7@VF2Z.%W,5'!W*
MJ9)RO)Q-ORONEU7<;G[ Y@587?.,8\&R+HK<5$)Z'BR%X%+O!TD>7@5UB1!S
M:6060O"G4%D(Z<H$M0/FIM.TSE S2&%E!GYOE:.'+/1U7D%K; W@N4B95%9Y
MNJ$!E.@@(8P,KW 8H/01LCRDY#)1Z*G%1LD=O.9D-)F37JJW,!!68&B/LQO@
M6&73LZ-G.3/2Z#D! 1'+9(FW=WJC1.6WJ<MRLI@?CB9R*1>SV60<'A\?3<.Q
M#,)H FJ^5-]U^:M(5\"6@P['>5FAKNGL6I45.%H83D+4#L1O=<G^N2XBHGX@
MP#P6<I@.Q=G3-ZAU;VI51G(S$*<0JB9B,OCX8G_WO-ZMJ=>[;^N3T\NSYP-Q
M"5;I=V42M!?X]_FKET]?O:2/+\_^(?[YZN*7WC*(^S\_?_7D#+^^_,?YQ=D#
M08F;\8EP.W#_I83E^_=#<?'J_+<'U-9KHW/Z#B)N(PM5@X# )N2PRO ]9W2C
M%B@Y_HZ"<-BJ=D&[$.J^15X/=E0JW+(:7J)Z-!#XWP-8$74M$XSJ^U2&Y1TE
M%AGHW+R#A"SC?,U4H'+9\[(R8/.1?&PB*Q \Z<QNGWG\"%,9-GM!,5N[PG9$
M50PRKZN;<WHV(_Y9LGIX<R>?U^XV*NW1>#AU:3J7[HA5$F&>HY\@D>2GVW'J
MD/*#?UX,QR-1@)^FYX?$^\C5RJ@54CV]!W!:.*9^X^"+LQ*9(!B'MGG/MQH\
MM@(PC<G$X:P9)\H\&2+.TXA^+G5'VD92F/Q,!:;&('PQ:)>!U ZFV^UR<6_X
M:4V$Z%:"?,JNVKE^[);)?8U.WE  8_05+C5J'6E@G0'F*L/<;.^09?E  U!P
M-=,2J*$0U"5Y@<V -BM.#Z0JTH!=8#"@T]PHJ[2&O0TM4TCX+]:K&.Y 8C13
M*@)[48<Q[KV5NE+YWJ0)^M8Q:#%SH4:75R@I 81Z$70)0=X_%'T)JX6$"XA&
MD2!MR?B5M)=:;NTK3KYYC&F=]@EG+4 ZC6\);K(# Y)VNGE7<AYUV(G[&D'U
MMMZB0NH.D>OKFDPP$4.KMZP-S,3X9%*]P2JQLIL0C?,$]@#W$&O#.!7#D!@-
M,"XI+))16#%0^A8)4#85\N%DK #@CUZ;I140!-<Y$ER>3##79:TZ!\;6N)7$
M:&&K=0'BA&TVD3H)(MYM#69G_W&%88L'),7@8DNI(_%"5I7X&9Y7 _'3V2ML
MVDKOL(]1;L,9VY!L-_+X^#J)RMC-_:G,Y$D"PC$Y;&D/#IC:!!PJ =$*(!P1
MK"(*Y>3A&)=Y!]F.>R]<+G%7<J*]82A>6T4;B"+>E" B('X#?R=H.QT) BL'
M[H^&0EIH?7=>@FLA*K6;'"$O>CB"/@\0[Q0@JIDN(< $Z36(4ZMF%2K#O%"U
MSBGIP=P/]50!;((G8;>7?A/HU4!,JAR0 *H6I4J.Q?U2O]VGSQB?YB U]/R#
M(>B>6UYLU8(>:!>[;7(A_M1M6@34O)_:1(E%DZ+:# Y> @M%##!&R6!7'!5,
M_BUG,A?P4R+3M%7,:UW6T*(,:PB5.S5ZO8R+B&K2.8UP+*R-0;M,1%N)^]P-
M=:'3L";K!Z!SPWZ?EKHQ\S?GHM:R:Y%N3A6U":J^0[Y#+=_[^=H0S+3!FL@J
M;HI;(;QR&FVOP-=@75W3+JA]<O'ZV6NY4D]@%E>G\+\MM]N[\5F>8ZGNX]O,
M00'W[0?8XKY<5EA6*Y.UW)0W=-N-\787"MN6>2Y4&2Q&6!W<B>6YB'??7AN=
M"%=(/+EC(;&_HC=,M3>1ORL8YM:R?%I\=-J(& 1ABWOB_OQ@?/2@DXB]->W8
MI&[OSPX6[WYNW#R'0&5;[$.C,1B2 [;1E)5M%ZV3GG796+0(-R9DOUP^UNL9
MX8H+Q;8+2+K8NUICI(#--H^XM)9O-DJE,M<_H$S.E!':[UG2-B- ;6;)IJVK
MQ'C3&G$D]MF669AQ2P3P96@%='\N6W];1M$/ &/YNP+9 *V"RWU' '+K,H!5
MK,,K1+R#]\Q'#L6K98NA>1_:S;E!4Q!EN+J%*H;&$/AQK+LK(XG6/P"99#@V
MF]Z#H<=:62&R!TA0X;I/.4\-/D.\S/N#O&UL=-A!^6@$=1"IX6X/%I2JJ'O=
MF__F)K?U$1S5QY"ERQM23+3Y(6YQB6$ VZ""N)D&5=MB+0J4O+6T!JN;PT*M
MVY7":K-7O3P:4B0!JC;*&P9Y[:*^,WW'H-9U#2I.QX2(D &-!U]4;DVMK; F
M5B&B" ^AC=$!7/V?TU]@"'38)#<0#9Y&D79FI5W!+O5$W$1 A3EHW;!MI$Z6
M=84&E\)9PG?9$M8:<+(SDU^;N;'1_<O=E!RR-*@'LJR8UW/^@Y8[E!GT*SE*
M!F6!B5OCHR$0TX9\$ =F@,MU4%<$/&%?2N:XH"OXNN0D2<G"EJ@51J4N-G?Z
M_"O 4N5E6B\K\HT*; 7E53J5$Q $PH](#(7<J#98)V%*C:F2INUN4/B_-4SG
M*4;*+U?U1F4#\>(I_+T,!^+9Z<5OK_"?RXO+01-X,36N5Q+I<>9H\R4T"S]!
MEZ^*&!8I20$MK38H'#B+)QL8A#C;*'$.P],5K,A@^]$7E@SA;^ '":L7(LW>
MF7\&)C7"A:&9@91>AG$.,8S7PE#8_?W)XGRO0*1@=X^: 1H!LP'W\6^,9)PC
M1GJ9U]+I'D2\<0W.(P-E2B#00^HAS*N6D1: [AH=#52%6*71&_)$.5L>"#>P
M1?03<<X2(",(ZQN73L1*;5;,-"#3 T:DG;YO35I.T-%3#GQ ,TT,U9;BH+0U
M5@Z41^/X,)1U>4O:JLC4*PJ,P0>GRL]>(GI!=@66'^.O:[55=>L@!L,14*)(
MD67LZA"NAU$:M]%"(?@&[G",6!A+7 ]8U69#D&<&_6K7X<T_?YD<@/T:.P/F
M#F A399LVC Q-UXR5;DQV)UJ%@DV.LYAS:'/<%/E5\C(M0S;;MY^:+7H_2W;
MS;S)9R1,/5JSRZ0@Z@4@!8TS*X%2B52)2/05@!10,>+[E^#@5./IT$OR)@T0
M%A!50"GJKM?BK74"0(B\I37R#BT!/3??^/[Q7W590;=OF=T8L$:!I<DLI$8F
M5"(G4G:)"[*D!?(IZ)2=>^^:P"?@D?\/)$29AA=S>:?&DIRN))I6]@ 8%D8F
M+Q!/"J9)C28:BEP"JHT?RW"%.H@E1F"W K6!LQXT,[)!;NA><-#L%Z7 D7EE
MY$ATAA5M7)[$6AM>"&8Q4@F:#PTHYZ$8,82T#PA+]B-5@-'P@BQHWN3@DAIU
M0>;*W=,OU_,)FEM!.8/-%0H&*!71VP@;$#O!=N+Q910DL%PYY^[:^4]Y)DVN
MK^%V-3/M79ME+4*DEP1)D.2A4N(\JL.JP5%;-54<)I&-G9Q@\84I8LH+.U[>
MH^6Q&A&+'4+P:A80P/H'.FHFO02=)(=A;20BS :=$?OD<\%_4-/2Y&J18D-\
M0VP;T6JH$9R!G7YH\0AONN6ZQ3JO(;A"T\1DN<RN*&%@<X@^1NGCZ#AO1:F0
M6'&@"[]<K6,6OXY,V7?V[MMD[]X0I\-57TY]+.-_<\U!OQH,_FL*N@C8@<5$
MP]BD3JS< V(#7-TH'F!B@YX(- K5SP; % 1Z]6'MFFUI[/PKXYAVOAW@ID/Y
MXB\R+4ZV4OGMC5\G\_&^1Z_],@V_OF)WEC9)N#0%G61[0^GE#[M%&BA1=.3:
M%4K(%)20B_.;L@^/3^+:!^?5M\I%'.>PK"ECQI#R&O 55P#*,F8L@Q\@E-/D
MBSD,BEUY4I0K!/(57"'*#V58VY +:V>X\TJG?%P<-04+'=N!=R?(>M2.U19M
M,"S"C@D&0 -+2:O>*UMIYP[F[DI5;<7)>Q3 V$)L$>"[8XC43!&@H?_,4XQ%
M"611L^A2M7T1#>7:"8*P<[31,-:H8IDI()(A!-410Y2=<M!N? K@/*" %D$4
M<8I@9@$)Y3!_U[F7BH?N$1&0-5DB)O>/U</<KYD<S]0JM_BL^W"WYJ>VA_<-
M0\0B@5NY>$)<U" 1XU$PWQ^[U;Q486UH?N+L+<:6*R5.0]K3\6(ZHY2A3'%T
MT=V=_1=2\]>U 5S-:)? TXVZ"W+3K46\0XW8WN.!+?MJU-QQR 3+=U1X42%'
MZ@A(C[;IET3EG:>H6FLPF8\'H^-I3]7N4K+55&HUQ5L#,EH=8[1=YG5;1=:6
M5?(K3,@4]0?F^=MV 6#"88))!N3T84 !\NZ\,S/>F3^,\-U@I:U-*.N20D,*
M:]HDFR6* ;F#C65KBXP8; P\DX$LE1!%,F\IR;S&^9I).-FRTCT;[(<#7#+7
M#(JL@;?ZL:<2>HGC&- V@)QB/$^24'*\W1@YYW92P'U?9:)C)Z Y=X7+/X%6
M?8VCWGM\VB^OYE*5($3^QJTZJ?U6@77'E@WZ==F[7P]@O/<Z[0CQJ?>=99:M
M_&R+.T@PTBZA*IT@NHP'3PD,5A'GF-GC CF;MT4/F&'&S[[XC5C21_5C/ZL+
M46UV]>B@?LRFQV9:VHH7MU*1J@ #E6TI7HN)V!E:YNJ,:UP8T+[V6BL="68#
M "<ZG3QT6'FEN4VIO JH>@?V)ZZJHGQX<.!V=&AL11FHYD&FUN4^U]@<\#^V
MA!86D\J;^KO>3@$Z[6]*T^NRLBBEM^I_'"T])?O?$"8?;]R?L/AN=RD^I<H"
MG5<JC#-.^CBC'%$VT(:=7ODKIU%:(HP\]$T</1%L#9O6D&FMH%2[2L]LEJ?#
M&35R1+D[<#B 46'TW2ROI$0#R'UB*W2;!"F]8^"?OTQH")AZ:"M &/O2@[L2
M$X.>V6EY6R_Q@><JZP*5O117:M/F(<@<V );[U28928]9+PI0(7%^;.7 _OY
MW%\1NG[^_!#_-YYP.'#^?#*U[;CL,K24@-&JI%DI!O:V FXKC\UA2.6?OG"'
M$^C\:N?$A7;;27DB+V_4S7[UNH&5LH5Z"6(+*IUNR@XQQMSB%%&4>OQ'OQ@3
MX1F=R,! ;V<#-^1[_M,2V>Z9K-M:^V1TW]T(OX](^;V#].O1>L3E;:_!3:3@
M!W* -T[XO8B_VW?PD[H-ZQ<_1<GV9W4H#DV0"T%LKPP>?]TO*UAU]"DVTTZ>
MQE8-4P1!-2\ZY01#2ED4@@,)&"%^9X0C^_'L"X T.I#NZ ,OT>+*YVW/[DV>
M6'3E#F9T2WDE%DMA@@[Q'YWTZX.40A=4TF4Y"QC/;V].7YS"8A_-3M"_6.\'
MKA#GU"2!7 E?YU4619D;+4O-*8QNDFCW$Y(:MC80S19J0)6'"42W 1O]%[^]
MV1_/1N #F >.:]@@<+$9W$5A%DQ'!SG9;/8#6ZR5$)F"6Y$A>Q92L7J!'O*^
M19S/PHO,8LL'_5';7*+CQ\Y7/^^G5.J!$6(+ KSS+R=;+IJ7<,O5<AXMP1B?
M1:B_6CW/,+C!TOM<F3<DGTSSB6_1A*@HC_R85TZ& TES@!-UHNR1F^A:NF,R
MC;B I-([H0D@Z10!0ED#WH6E,52/UN#YWV!_&NC>(JLM6>8.VA-&Q&HZE$9T
MWQ.UR3/GXQG/-0+-(04(<1U0Q1&%\K!G&ZN>K(R:V_47(U8R 4?OX4%XP%1U
M040F1$.X'5C;B<J+*KJEYX[8'(IG,&O*9%.UB$LJ0[RT7J_]0.-NK-:P>4=R
M?6N2ZUW'JK^  W"; PNSEB;:?Y[G5/E#96&4@_]Z)X3,D2X%0URC."Q&>@@+
M*U _:4:)G5'9S&CHS8Y#U:U64BH6(7OK/6@=A5%,_&L,3TG D)1G?9"N(#1"
M6M,7X_YX$+W:.#E5(/AXV&N)Y#(I_N3H= ??W-+,4Y]F%O?Q/JO-W=N=U603
MU+0^/OL -KO3C7]SV\DZUECBA"5G6*>!A5--Z2K5\S#;WHFLEF(-:*ULJJ-L
M!^@T.)'>U-;8;P(P<&"B^I<=,;A]O4ZB_D5,YJ<[VF:BM7_5UA_T+X.4;%U"
M[>I?Q(3"UC5P6EA%N7W=5IIL?6'0\&ZW;?)_[1AQ&>^:-14YN&MTV E\@3VN
M0"<Q8 =X,\!.EAHT$>MJWI)N-.&OOWE\,VD+[_/F%KV#L+7F\DT9E,2QL R"
MOG$[34X-%<(J6_L\PCK\LM<!>4#>(-O8S2.P:3;R.ZU TNN'P&- T,!5G#17
M<O"]IORI>ZU:F\,QY+LU^ 9-]#7J3K'AY[:ZK^JMA?%7P]I-WFUG+ $N:B9N
M!OZ]F$$QD3OHBIP((@R9 2#@8\Y*I@T29MV4%C'%>8')2S(&2T)0%;_ C847
M"0"UZKTEM>T.%YQKS-DROJ^1]U.'WC.<?FD/ _?S6"6_$[9!<;*+DKPG[>E<
M6TYF2XUL;5F(!_3I32'<G.6L^*P S:)F ADE*B\0!G9G[[W+@M;;5H+TWM7%
MCBS;>.#OS@,<BO.L@;$#:JV_Q$8MD77-A35AO*T@6 H97-I%BWUA,6'ME?O%
M"#0_>T"@/6\9:A/6J:U5][:I2]=LF,I.-ORB@[)."Y?.-K=9CJ]:(4\3/ *P
MBK%XU#I'7F+:*,QF^^HQZ"B2E7ZG+>B [3DY-F>H2_4*WQGB#&9^NXEEP9<E
MA'/HWG!,F)7#NLQ.O.>EZ'BPE%-[QV [FMV2_)4UO\C[VC-/@/6YC!/A_@ K
MAI%-=2J 'HL+.#'\Q@.$B%7L2UYP@E%SJ,5BM-MF[%ZQ@4.A-S'P4D%<6:<!
M5SSANQ*ZY[CQQ08&QUW9F*<KCHW\LAWMVU >);4JD'>&X4&,9,=Z@2]F>,:%
M(G[&!<5A"=8B6UGRE Z$#"^'OH?"D32NZ"=\XP3Y_J%X 0N)CI.V%(PO%2(3
M:8I1',5BJFI/P"$7'\&B4DL]/539M39YQEX]LZ@1ST'QA&!=S<J6=6-VEZH2
M7);WW=(74/U,7=@#",W1[+[46]?A5L9S.[)T3CFRU=8[8@0']^WI*LK(\X[:
M:?3BV.Z&\\$?*CH-9<TG27T))3+_XPCH$/=3%17K]K]K;;&/+,!%A)0Z2.2:
M2\]1!"E_G@<)5KM:$H)?4"6*&JZ&R+)GMP.]=:R8[>BRY79VN*"XVYT@?,N@
MD_%?Z[*?*_]4Q.3WVM@_7FWLYR5+?D*<#YCGX=<,!A[53<E&^2Y"ZF.2[DV=
MR(5*V,A^AIEJ\S>?M?NJ^3<:,!XHE)]C6RXKA>=+M!+/E?I<,G");S0"^/W)
M%W*+GMU2W=OX6MB'TBW/,%%J6X:8SKVM%S[X-EV<[/C]>!]0__&%*J=@)2X
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MKL]CAGYR7_^29T"Q12MQJ=4Z0]HR"G=B]0',^.KZ"9:9'<F"'I'=5EOR@A)
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M5"'6@X"& %?>7LI!N[_.H)6&WQY4S,<L+U#Z#UDYVP<^H$UU PA<>U]9ASC
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M_2D\7& J.&=KJG[5,Q^%\V+4.CDP\*1O4TR#Z(X46F[(':\)2TE,"N'5;ZC
MG"#SLLP-T$=X"P">RHUE-!W=+>.UOI#[7&..I2TQC7'Y#PKY9QU^.Y_7[I.;
M@6JA?$!XNK<NJT%_7Q[M \A]+H/_59ZO,6_M!B?<[@D+'+PSFDH\S!^6;-HE
M+^VEG8:U);P6&^2?SG<1^2+_I/WI?U!+ 0(4 Q0    ( %$Y@E@:=72._Q4
M )Z5   1              "  0    !E9C(P,#(U-CDR7SAK+FAT;5!+ 0(4
M Q0    ( %$Y@EB_,J7/D1L  /5U   5              "  2X6  !E9C(P
M,#(U-CDR7V5X.3DM,2YH=&U02P$"% ,4    " !1.8)85-+!U4(#   V#P
M$0              @ 'R,0  <F]I=BTR,#(T,#0P,BYX<V102P$"% ,4
M" !1.8)8!_#EBGH(   P5@  %0              @ %C-0  <F]I=BTR,#(T
M,#0P,E]L86(N>&UL4$L! A0#%     @ 43F"6*\TN_K:!0  [SX  !4
M         ( !$#X  ')O:78M,C R-# T,#)?<')E+GAM;%!+!08     !0 %
+ $<!   =1      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ef20025692_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="roiv-20240402.xsd" xlink:type="simple"/>
    <context id="c20240402to20240402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2024-04-02</startDate>
            <endDate>2024-04-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20240402to20240402"
      id="Fact_d723cebd2fc543188871c1f3753ce51e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20240402to20240402"
      id="Fact_779593046f8f456ea1008eba928538e6">0001635088</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20240402to20240402"
      id="Fact_3518fcbc007144b582ed34fdc2500781">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20240402to20240402"
      id="Fact_c79f5a6926824d4eb1811ac4419bd40c">2024-04-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20240402to20240402"
      id="Fact_ba4f731eefdb4672854dab27f2994e19">Roivant Sciences Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240402to20240402"
      id="Fact_0e1c454b261f43a4b456b27bafe0d60f">D0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20240402to20240402"
      id="Fact_5acfeea8e0474a059dabaddb683c2c98">001-40782</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240402to20240402"
      id="Fact_49c55ff55bd84c3a87fac92e60ebb5e5">98-1173944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240402to20240402"
      id="Fact_db920de0c6f54c5dbb4818486f404f4a">7th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20240402to20240402"
      id="Fact_1b33b5ec366441b7be1e125a5694b881">50 Broadway</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20240402to20240402"
      id="Fact_940480e8a5ae4061960547ac0827ccb3">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240402to20240402"
      id="Fact_ab6ffae1f0384fac8551d31ce7e18a8d">SW1H 0DB</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="c20240402to20240402"
      id="Fact_93257f5c88e847fda44225a71cc972a4">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="c20240402to20240402"
      id="Fact_04fd9c5890044858b9f689edeab8f472">207</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240402to20240402"
      id="Fact_bdaa701cdbc844569779ec1599cb0255">400-3347</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20240402to20240402"
      id="Fact_59999e08c6264086894ade88028b7cf8">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20240402to20240402"
      id="Fact_0d7f63f9c88d4b5aaf80ea8a5820bcad">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20240402to20240402"
      id="Fact_3912ea0b6a4e49b494c3ea4c0b375841">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20240402to20240402"
      id="Fact_a36226a17de64c4289e1f0f4a03f96dd">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20240402to20240402"
      id="Fact_bf1fa18931494d73a4be2e0f4b414dc7">Common Shares, $0.0000000341740141 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240402to20240402"
      id="Fact_8202e2bab94b47ac852e09ab0f879fd4">ROIV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240402to20240402"
      id="Fact_c4a0f630e4ec46b3a7fabc05e5879f1d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240402to20240402"
      id="Fact_545c6018c4244a35893e5f8688169ba2">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
